Pleasanton, CA, United States of America

Shankar Kumar

This inventor holds 31 USPTO granted patents and 4 published patent applications, plus 12 CIPO patents and 16 EPO patents. Top assignees: The University of Texas System, Abbvie Inc., Gene Techno Science Co., Ltd.. Active years: 2007-2023.

USPTO Granted Patents = 31 (Patent Applications = 4)

% Patents Active = 61.3

CIPO Patents = 12 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 345(Granted Patents)

Location History:

Watertown, MA (US) (2007 - 2009)
Newton, MA (US) (2009)
Pleasonton, CA (US) (2013)
Pleasanton, CA (US) (2007 - 2023)

Company Filing History:

6 out of 5,622

The University of Texas System

Gene Techno Science Co., Ltd.

patents

4. 3 out of 8,568

Massachusetts Institute of Technology

patents

5. 3 out of 116

The Trustees of Boston College

patents

6. 2 out of 4,186

Abbott Laboratories Corporation

patents

7. 2 out of 10

Chiome Bioscience Inc.

patents

8. 2 out of 136

Kaken Pharmaceutical Company, Ltd.

patents

9. 2 out of 652

National Cheng-Kung University

Livtech Inc. — Teikyo University Biotechnology Research Center

Pinteon Therapeutics Inc.

patent

16. 1 out of 71

Progenics Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

Areas of Expertise:

Humanized Antibodies

Phosphorylated Tau Antibodies

Anti-OX40 Antibodies

Interleukin-13 Binding Proteins

Anti-TROP-2 Antibodies

Nucleic Acid Encoding Antibodies

Cytotoxicity Mediation

Thermoelectric Properties

Metal-Doped Semiconductor Nanoparticles

Antibodies to CD122

Anti-hDlk-1 Antibodies

Amphiregulin Antibodies

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11591385 - Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies (2023-02-28),

2. 11344621 - Interleukin-13 binding proteins (2022-05-31),

3. 10851173 - Anti-OX40 antibodies and methods of using the same (2020-12-01),

4. 10202461 - Anti-human TROP-2 antibody having an antitumor activity in vivo (2019-02-12),

5. 10196450 - Anti-OX40 antibodies and methods of using the same (2019-02-05),

6. 10086076 - Interleukin-13 binding proteins (2018-10-02),

7. 9695246 - Anti-OX40 antibodies and methods of using the same (2017-07-04),

8. 9683036 - Humanized anti-IL-20 antibody and uses thereof (2017-06-20),

9. 9592293 - Interleukin-13 binding proteins (2017-03-14),

10. 9527917 - Nucleic acid encoding anti-OX40 antibodies (2016-12-27),

11. 9427464 - Anti-human TROP-2 antibody having an antitumor activity in vivo (2016-08-30),

12. 9303086 - Anti-hDlk-1 antibody having an antitumor activity in vivo (2016-04-05),

13. 9163085 - Anti-OX40 antibodies and methods of treating cancer (2015-10-20),

14. 9028830 - Antibodies to CD122 (2015-05-12),

15. 9006399 - Anti-OX40 antibodies and methods of using the same (2015-04-14),

Title: Unveiling the Innovations of Shankar Kumar

Introduction:

Shankar Kumar, a prolific inventor based in Pleasanton, CA, has made significant contributions to the field of biotechnology and healthcare with 28 patents to his name. His cutting-edge work has been pivotal in advancing methods and compositions for neurological disorders and immunotherapy.

Latest Patents:

1. **Methods and Compositions for the Generation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies**: In this patent, Shankar Kumar introduces conformation-specific antibodies designed to bind to and neutralize the activities of phosphorylated-Threonine 231-tau protein (pT231-tau). These antibodies hold promise in treating neurological disorders associated with elevated cis-pT231-tau protein expression.

2. **Interleukin-13 Binding Proteins**: Shankar Kumar's innovation in this patent revolves around IL-13 binding proteins. His work focuses on developing antibodies, including chimeric, CDR grafted, and humanized antibodies with high affinity for hIL-13. These antibodies are adept at neutralizing hIL-13 activity and have applications in detecting and inhibiting hIL-13 activity in disorders where it is detrimental.

Career Highlights:

Having worked at institutions like the University of Texas System and AbbVie Inc., Shankar Kumar has honed his skills in research and development. His expertise in biotechnology and pharmaceuticals has been instrumental in pushing the boundaries of innovation.

Collaborations:

Throughout his career, Shankar Kumar has collaborated with esteemed professionals in the field, including Naoya Tsurushita and J Yun Tso. These collaborations have fostered a culture of innovation, leading to groundbreaking inventions in healthcare and biotechnology.

Conclusion:

In conclusion, Shankar Kumar stands as a beacon of innovation in the realm of biotechnology and healthcare. His patents exemplify his commitment to pushing the boundaries of scientific knowledge and developing solutions that have the potential to impact countless lives.